Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2017-07-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management using temporarily idle raised funds and the company's own funds. It details the purchase of various low-risk financial products from banks, including amounts, expected returns, and risk control measures. The document references a shareholder meeting resolution approving the cash management plan and provides detailed tables of financial products purchased and their status. There is no indication that this is a full financial report, audit report, or earnings release. It is not a report publication announcement since it contains substantive details about the cash management activities. The document is an update on the company's capital management activities, specifically about the use of funds and investment in financial products. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6198 characters) and detailed content support this classification with high confidence.
2017-07-14 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management for temporarily idle raised funds and own funds. It details the purchase of low-risk financial products, including amounts, expected returns, and risk control measures. The document references a shareholder meeting resolution approving the cash management plan and provides detailed information on the financial products purchased and their status. It is not a full financial report, audit, or earnings release, but rather a specific update on capital management activities related to fundraising and use of funds. The document length is 4249 characters, which is sufficient to provide substantive details rather than a mere announcement of a report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-06-16 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management for temporarily idle raised funds and own funds. It details the purchase of low-risk financial products, including amounts, expected returns, and risk control measures. The document references a prior 2016 annual general meeting resolution but does not contain comprehensive financial statements or detailed financial performance data. It is a disclosure about the company's cash management activities and investment in financial products rather than a full financial report or earnings release. The document length is 4409 characters, which is relatively short and focused on a specific financing activity. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's use of funds and cash management activities.
2017-06-01 Chinese
关于完成工商变更登记并取得换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business registration change and the issuance of a new business license. It includes details such as the new unified social credit code, company name, type, address, legal representative, registered capital, establishment date, business scope, and other registration information. There is no financial data, no mention of financial results, no shareholder voting results, no management changes, no legal proceedings, no capital changes, and no reference to any report being attached or published. The document is a regulatory announcement about administrative changes related to business registration. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-06-01 Chinese
关于参加河南辖区上市公司2017年度投资者网上互动交流活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor interactive communication event regarding the 2016 annual report and other company matters. It mentions that the 2016 annual report has already been publicly disclosed on April 17, 2017. The document details the meeting time, location, participants, and how investors can join the online event. It does not contain the annual report itself or detailed financial data, but rather is an announcement about an investor communication event related to the annual report. The document length is short (955 characters), and it serves as a notice of an event rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and communication notice, not as the Annual Report (10-K) or an Investor Presentation (IP).
2017-06-01 Chinese
2016年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the implementation of the 2016 annual equity distribution (dividend payment) by the company 普莱柯生物工程股份有限公司. It details the dividend per share, relevant dates for dividend distribution, tax treatment for different shareholder categories, and the method of dividend payment. It also mentions the approval of the dividend distribution plan at the 2017 shareholders' meeting. The document is relatively short (2332 characters) and focuses solely on dividend distribution details without containing comprehensive financial statements or broader annual report content. Therefore, it fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2017-05-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.